'EXEL' - (Exelixis prices public offering of common stock Deal In Brief)
Aug 10, 2012 (Datamonitor Financial Deals Tracker via COMTEX) -- Update on
August 9, 2012:
Exelixis, Inc., a US-based biotechnology company, has priced its concurrent
underwritten public offering of 30 million shares of common stock at a price of
$4.25 per share to raise gross proceeds of $127.5 million.
Exelixis has also granted the underwriters a 30-day option to purchase up to an
additional 4.5 million shares of its common stock.
Concurrently, Exelixis has also priced public offering of $250 million aggregate
principal amount of its 4.25% convertible senior subordinated notes due 2019.
Announcement (August 6, 2012):
Exelixis is planning to issue 20 million shares of its common stock in an
underwritten public offering.
Exelixis is also planning to grant the underwriters a 30-day option to purchase
up to an additional 3 million shares of common stock.
Goldman, Sachs & Co. and Cowen and Company are acting as joint book-running
managers, while Piper Jaffray & Co., Stifel Nicolaus Weisel and William Blair &
Company, L.L.C. are acting as co-managers for the offering.
Deal Value (US$ Million) 127.5 &nb sp;
Deal Type IPO
Sub-Category Secondary Offering,Pricing
Deal Status Announced: 2012-08-06
Deal Participants
Target (Company) Exelixis, Inc.
Deal Rationale
Exelixis will use net proceeds from this offering for general corporate
purposes, including for clinical trials, research and development, capital
expenditures and working capital.
Offer Price ($ per share) 4.25
No. Shares Issued 30000000
(c) 2001-2007 Datamonitor. All rights reserved. Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon.
-0-
Source: Comtex Wall Street News
News 
Market Data 
Discover 
